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A Long Term Results of External Beam Radiation Therapy  
in Hemophilic Arthropathy of the Ankle in Children
Bleeding into joint space is critical to develop hemophilic arthropathy. To reduce the 
frequency of bleeding in the ankle joint of children with hemophilic arthropathy, low dose 
external beam irradiation was performed for 37 patients. Among them, 35 patients 
followed-up for longer than 1 yr (median 87 months) were enrolled for analysis. The 
average number of bleedings per month was 3.6 during one year prior to radiation 
therapy. After radiation therapy, it was decreased to 2.1 during the first year, after then it 
was maintained in the range of 1.0 to 1.5 until the tenth year. The bleeding frequency was 
reduced to 42% at the first year and it was maintained in the range of 58% to 73% from 
the second to the tenth year. Especially the patients who had 3 or more bleedings per 
month, and who had MRI score more than 3 showed significant decreases. During the 
follow-up period, growth disturbances and secondary malignancies were not found. 
External beam radiotherapy can be considered for the hemophilic patients with surgical or 
isotope therapies are not amenable.
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ORIGINAL ARTICLE
Oncology & Hematology
INTRODUCTION
In patients with hemophilia, 85% of all bleeding events occur in 
joints, and the joint-related morbidity remains the largest source 
of disability (1). Furthermore, the incidence of target joints, which 
is defined as to have 3 or more bleeds within 3 months, increas-
es with age approaching up to 20% by age 18 yr (2). The blood 
in the joint space initiates hypertrophy of the synovium, release 
of proteolytic enzymes, and hemosiderin deposits. Contractures 
can also occur, leading to the end-stage of hemophilic arthrop-
athy (3). After repetitive bleeding, the hemarthrosis results in 
chronic synovitis, epiphysial overgrowth, and the destruction  
of cartilage. The repetitive joint bleeding eventually leads to a 
vicious cycle of hemarthrosis-synovitis-hemarthrosis (4). Thus, 
managing the number of instances of bleeding into the joint 
space is critical for prevention of the vicious cycle of hemophilic 
arthropathy. 
  Currently, arthroscopic or radioisotopic synovectomies with 
or without factor infusion are the mainstay of treatments for 
hemophilic arthropathy. However, for patients with inhibitory 
antibodies, multiple affected joints, tight regulation of factor re-
placement, limited resources, or in circumstances where reha-
bilitation cannot be ensured, treatment options more feasible 
than those mentioned above are warranted.
  In the meantime, patients with hemophilic pseudotumor, 
which is defined as progressive cystic swellings caused by recur-
rent hemorrhage, treated with external beam radiotherapy 
(EBRT) have been reported to have complete remission even 
with very low administered doses (5, 6). In our institution, a con-
siderable number of hemophilic pseudotumor cases showed 
decreased bleeding frequencies in the irradiated joints. Thus, 
even though the mechanism of reduced joint bleeding after 
EBRT is not well understood, EBRT was attempted to reduce 
bleeding frequencies for hemophilic patients with repetitive 
bleeding in ankle joints that were not amenable to arthroscopic 
or radioisotopic synovectomies. 
  In the previous report with hemophilic arthropathy patients 
treated with external beam radiotherapy with one year follow-
up, the bleeding frequency was reduced in thirty-three cases 
among forty-one joints (7) and the patients aged younger than 
11 yr (n=23) showed better results than 11 yr or older patients 
(n=18). However, the previous report included variable joints 
(35 ankle joints, 3 knee joints and 3 elbow joints) with variable 
ages (ranged from 4 to 27 yr) and the follow-up period was too 
short (one year) so that it was not sufficient to evaluate the ef-
fect of EBRT on bleeding frequency of the hemophilic arthropa-
thy patients.
  Therefore a long term follow up results of EBRT for hemophil-
ic arthropathy were retrospectively analyzed for the examina-
tion of bleeding frequencies and related morbidities such as 
bone growth or secondary malignancies.Kong M, et al.  •  External Beam Radiotherapy in Hemophilic Arthropathy 
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MATERIALS AND METHODS
From 1997 to 2006, a total of 37 hemophilic patients under age 
18 yr were treated with external beam radiation therapy. Among 
them, 35 patients were followed-up for longer than one year. The 
number of patients includes 24 patients who were enrolled for 
previous report (7). This retrospective study was approved by 
the Institutional Review Board at the Kyung Hee Medical Cen-
ter (KMC IRB 1014-02). 
  Detailed patient data, including age at the time of radiother-
apy, type of hemophilia, involved joint, initial radiographic joint 
stage by plain radiography according to the Arnold-Hilgartner’s 
(A-H) staging system (8), joint scores by MRI according to the 
suggestion of Funk et al. (9), and pretreatment bleeding frequen-
cy were reviewed retrospectively. 
  All patients were assessed by pediatric hemophilia specialists, 
an orthopedic surgeon, and a radiologist to decide treatment 
options. All children with moderate or severe factor-deficiency 
were eligible for this protocol if they had moderate to severe 
changes in a target joint as manifested on a physical examina-
tion and plain radiographs of the joints. A target joint was de-
fined as a joint in which clinically evident bleeding, as assessed 
by patient, parent and/or provider, had occurred 3 or more times 
in a 3-month period (2). However, all of the patients enrolled to 
external beam radiation therapy were classified to have target 
joints, so we further defined the patients with joint bleeding 3 
or more times per month to have a “critical target joint” . These 
patients were considered to have a higher probability of not re-
spond to conventional therapy and may develop profound dis-
abilities.
  External beam irradiation was performed with a 6 MV radi-
ography by Clinac 2100C (Varian Co., Palo Alto, CA, USA). The 
upper margin of the irradiated field was 2 cm above the epiphy-
seal plate of the distal tibia and the lower margin was 3 cm be-
low the distal fibular tip to encompass the entire joint space 
(Fig. 1A). The fraction size and total dose were decided based 
on the patient’s age and epiphyseal status. The radiation doses 
for patients younger than 11 yr were limited to no more than 9 
Gy in order to prevent possible bony growth disturbance. Dose 
fractions used were 1.5 Gy for 28 patients, 2 Gy for 6 patients, 
and 3 Gy for 1 patient. Total doses administered were 9 Gy for 
28 patients, 12 Gy for 2 patients, 18 Gy for 1 patient, 20 Gy for 3 
patients, and 30 Gy for 1 patient. An 18-yr-old patient with se-
vere pain and a pseudotumor in the distal tibia was treated with 
30 Gy in 3-Gy fractions. 
  The patients were followed regularly to monitor their bleed-
ing and any morbidities related to the treatment. At every visit, 
the treated joint was evaluated clinically for range of motion, 
presence of pain, and the frequency of bleeding during the pe-
riod. Also, the patients were followed to monitor any effect on 
bone growth and any development of neoplasia. Follow-up ra-
diological studies were not done routinely, unless clinically in-
dicated.
  Student t-test, Kaplan-Meier analysis, and Cox regression 
analysis were used for data analysis. P value <0.05 was consid-
ered statistically significant.
A B
Fig. 1. Image of treated ankle joint. (A) The simulation film for the radiation therapy. (B) Coronal T1-weighted magnetic resonance image showing prominent areas of hemosiderin, 
hyperplastic synovium adjacent to the ankle joint, some erosion, and small amount of effusion to give the score 6.Kong M, et al.  •  External Beam Radiotherapy in Hemophilic Arthropathy 
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RESULTS
The number of patients treated at the left, right, and at both an-
kle joints were 12, 13, and 10, respectively. Ten patients had in-
hibitors for the hemophilic factor. The median age was 9.1 yr, 
ranging from 4 to 18 yr. The Arnold-Hilgatner’s stage III was 15, 
while IV was 20. MRI evaluation before radiotherapy was per-
formed in 26 patients, in whom there were 12 affected joints 
with MRI scores higher than 3, and 14 with scores of 3 or less 
(Table 1). 
  The average number of bleedings per month during the 1 yr 
period prior to radiation therapy was 3.6. After radiation thera-
py, the frequency was decreased to 2.1 during the first year, af-
ter which time it was maintained in the range of 1.0 to 1.5 until 
the tenth year (Fig. 2). The bleeding frequency was reduced to 
42% at the first year and maintained in the range of 58% to 73% 
from the second to the tenth year. 
  The patients were classified into two groups according to the 
number of bleedings during the 1 yr period prior to EBRT. As 
mentioned above, patients with 3 or more bleedings per month 
were considered to have a critical target joint. Before EBRT, 18 
patients were defined to have a critical target joint and 17 pa-
tients were not. In patient group with critical target joint, the av-
erage number of bleedings per month during the 1 yr period 
prior to radiation therapy was 5.0. After radiation therapy, the 
average number of bleedings was decreased to 2.7 during the 
first year, after which time it was maintained in the range of 1.3 
to 2.0 until the tenth year. In patient group without critical tar-
get joint, the average number of bleedings per month during 
the 1 yr period prior to radiation therapy was 2.0. After radiation 
therapy, the average number of bleedings was decreased to 1.5 
during the first year, after which time the number of bleedings 
was maintained in the range of 0.6 to 1.5 until the tenth year (Fig. 
3). The patients with critical target joint showed a statistically 
significant reduction in bleeding frequency compared to the 
patients without critical target joint (P=0.018) (Fig. 4). However, 
some of the patients initially did not have critical target joint 
were found to develop critical target joint after radiation thera-
py. In these patients, the critical target joint was found in 11.7% 
for the first year and it was found until fourth year after radia-
Table 1. Patient demographics
Patients treated  37
Patients followed-up  35
Follow-up (months) 10-120 (median: 87)
Type of hemophilia A: 35 B:0
Age at radiotherapy (yr) 4.0-18.0 (median: 9.1)
Joints (n) Left: 12, Right: 13, Both: 10
Patients with inhibitors (n) 10
MRI score (n) 3 or less: 14, More than 3: 12
A-H stage (n) III: 15, IV: 20
Radiation dose (Gy) 9-30 Gy (median: 9 Gy)
MRI, magnetic resonance imaging; A-H, Arnold-Hilgartner.
A
v
e
r
a
g
e
 
n
u
m
b
e
r
 
o
f
 
b
l
e
e
d
i
n
g
s
 
p
e
r
 
m
o
n
t
h
 
d
u
r
i
n
g
 
t
h
e
 
y
e
a
r
Years
3.6
2.1
1.4 1.5 1.5
1.2
1.0
1.2
1.4
1.1
1.4
  Pre  Post 1  Post 2  Post 3  Post 4  Post 5  Post 6  Post 7  Post 8   Post 9     Post 10
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
Fig. 2. The average number of bleedings for each year. 
Before radiation therapy, the number of bleeding was 3.6 
per month. After radiation therapy, the average number of 
bleedings was decreased to 2.1 for the first year, and then 
the number was maintained in the range of 1.0 to 1.5 until 
the tenth year.
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1.3 1.5 Fig. 3. The average number of bleeding for each year in 
patient group with pre-EBRT bleeding frequency 3 or more 
and pre-EBRT bleeding frequency less than 3. After radiation 
therapy, the average number of bleeding was maintained 
in the range of 1.3 to 2.7 in patient group with pre-EBRT 
bleeding frequency 3 or more, 0.6 to 1.5 in patient group 
with pre-EBRT bleeding frequency less than 3, respectively.Kong M, et al.  •  External Beam Radiotherapy in Hemophilic Arthropathy 
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Fig. 4. The joints of group with pre-EBRT bleeding frequency 3 or more per month 
showed statistically significant decreased bleeding frequency (P=0.018). The patient 
was defined to have sustained bleeding when the bleeding frequency did not show 
statistically significant improvement in relation with pretreatment bleeding frequency 
by T-test.
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Fig. 5. The percent of patients having critical target joint 
was in the range of 0% to 11.7% from the first to the tenth 
year in patient group with pre-EBRT bleeding frequency 
less than 3 per month. In patient group with pre-EBRT 
bleeding frequency 3 or more, the range was 0% to 33.3%. 
Patients with bleeding frequency less than 3 per month 
were well maintained without critical target joints from 5 yr 
after radiation therapy.
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Fig. 6. Joints of the group with Arnold-Hilgatner’s stage IV show statistically significant 
decreased bleeding frequency (P=0.004).
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Fig. 7. Joints of the group with MRI score more than 3 show statistically significant 
decreased bleeding frequency (P=0.012).
tion therapy. In the patients with critical target joint, those per-
cent was 33.3% for the first year and range of 0% to 33.3% until 
eighth year (Fig. 5).
  The patients were also classified into two groups according to 
their Arnold-Hilgatner’s stage (stage III vs IV). Fifteen joints were 
in Arnold-Hilgatner’s stage III, and 20 joints were in stage IV. Post-
EBRT average bleeding frequencies were compared between 
the two groups. The joints of the group with Arnold-Hilgatner’s 
stage IV showed a statistically significant decreased bleeding 
frequency compared to patients with stage III (P=0.004) (Fig. 6).
  Magnetic resonance imaging evaluation before radiotherapy 
was performed in 26 patients, and the patients were classified 
into two groups according to MRI score (≤3 vs >3). There were 
14 patients with an MRI score of 3 or less, and 12 with an MRI 
score greater than 3. The patients with an MRI score of higher 
than 3 showed a significantly reduced bleeding frequency com-
pared to patients with lower MRI scores (P=0.012) (Fig. 7).
  The patients were further classified according to age (19 pa-
tients younger than 10 yr vs 16 patients over 10 yr old), and radi-
ation dose (27 patients receiving less than 10 Gy vs 8 patients re-
ceiving 10 Gy or more). There was no statistically significant dif-Kong M, et al.  •  External Beam Radiotherapy in Hemophilic Arthropathy 
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ference according to age (P=0.331) or radiation dose (P=0.447). 
On multivariate analysis, only pre-EBRT bleeding frequency 
(P=0.029) and MRI score (P=0.025) showed statistically signifi-
cant relationship with decreased bleeding frequency (Table 2).
  During the follow-up period, growth disturbances and sec-
ondary malignancies were not found in any of the patients.
DISCUSSION
The primary management of hemophilic hemarthrosis is di-
rected to stop bleeding with immediate factor replacement. To 
control recurrent bleeding, it is necessary to maintain prophy-
lactic factor replacement, but prophylactic clotting factor infu-
sion has limitations. In contrast to the widespread availability of 
clotting factor in the western world, the supply of clotting factor 
is not sufficient in some countries. It is estimated that approxi-
mately 75% of hemophilic patients do not receive proper treat-
ment (10) partly because of the high cost of these products (11). 
Furthermore, after the development of a target joint, mean fac-
tor VIII usage needs to be increased by approximately 116% (12). 
Furthermore, presence of antibodies against the factor may ham-
per the prevention of joint bleedings. With these reasons, the 
usefulness of factor replacement in the control of repetitive joint 
bleeding is more or less limited.
  The use of arthroscopic synovectomy to control joint bleed-
ing showed an approximately 70% reduction in instances of 
bleeding with markedly less frequent loss of joint motion than 
open synovectomy (13). However, in patients with advanced 
arthropathy and fibrosis, extensive debridement is required to 
reduce the chance that the arthroscopic synovectomy could 
become complicated by significant hemorrhage in the periop-
erative period (14). Furthermore, the procedure may require 
higher doses of clotting factor and hospitalization (15). In addi-
tion, this procedure is not easily performed on children because 
small joints such as ankle joints are less accessible to arthroscop-
ic procedures. Young children may also be less able to cooper-
ate with postoperative physical therapy after arthroscopic syno-
vectomy, which could result in a limited range of motion for the 
joint (14). The removal of synovium may reduce the rate of pro-
gression of damage, but the joint damage intrinsic to the carti-
lage will continue to proceed in a pediatric patient (10). 
  For nonsurgical management, radioisotope (RI) synovecto-
my is currently in use with remarkable results. In pediatric pa-
tients, Mathew et al. (16) reported that they observed marked 
improvement in 13 of 17 procedures and indicated that the pro-
cedure was feasible, safe, and efficacious in the treatment of 
hemophilic arthropathy in pediatric patients. However, the po-
tential complications of RI synovectomy include leakage of the 
isotope and accumulation of small radioactive particles in the 
surrounding lymph nodes and reticuloendothelial system (17). 
Also, joint immobilization after the procedure is required to min-
imize leakage (18). As with the concerns relating to factor replace-
ment, a large portion of hemophilic patients worldwide do not 
have access to RI synovectomy, either due to limited availability 
or due to its high costs (19).
  Thus for patients with inhibitory antibodies, multiple affected 
joints, tight regulation of factor replacement, limited resources, 
or in situations where rehabilitation cannot be ensured, a more 
feasible treatment option than surgical arthroscopy or RI syno-
vectomy is needed. 
  In the current report, the patients showed considerable re-
duction in bleeding frequency, so that the number of bleeding 
per month was reduced to 42% of the number of before EBRT 
at the first year and maintained in the range of 58% to 73% from 
the second to the tenth year. The results are slightly better than 
previous report where the number of bleeding per month was 
decreased to 55% of the number of before EBRT (from 2.52 to 
1.4). However, previous report (7) included variable joints (35 
ankle joint, 3 knee joint and 3 elbow joints) with variable ages 
(ranged from 4 to 27 yr). The difference may come from that the 
only patients under age 18 yr were enrolled to the current anal-
ysis. In the previous report, we reported that there was a tenden-
cy of frequent bleeding for the patients younger than 11 yr. Thus 
it is suggested that the response to radiation is better in younger 
patients. 
  Pre-EBRT bleeding frequency, Arnold-Hilgatner’s stage, and 
MRI score were found to be prognostic factors affecting post-
EBRT bleeding frequency reduction by univariate analysis, while 
only pre-EBRT bleeding frequency and MRI score were identi-
fied as prognostic factors affecting post-EBRT bleeding frequen-
cy reduction by multivariate analysis. The average post-EBRT 
bleeding frequency reduction rate was slightly lower than the 
reported reduction rates of radioisotope synovectomy and ar-
throscopic synovectomy. However, the authors did not find any 
EBRT-associated complications such as loss of joint motion, 
transient flu-like symptoms, localized joint pain, joint swelling, 
infection, or periprocedure hemarthrosis, and EBRT does not 
necessitate hospitalization or joint immobilization and requires 
no coverage with clotting factor. 
  In addition, possible bony growth disturbances, which may 
be induced by radiation, are another major concern. In children, 
Table 2. Prognostic factors affecting post-EBRT bleeding frequency
Variables
Patient 
distribution
P value
Univariate 
analysis
Multivariate 
analysis
Pre-EBRT bleeding frequency
   (<3 per month/≥3 per month) 17/18 0.018 0.029
Arnold-Hilgatner’s stage (III/IV) 15/20 0.004 0.224
MRI score (≤3/>3) 14/12 0.012 0.025
Age (<10 yr/≥10 yr) 19/16 0.331 0.842
Total dose (<10 Gy/≥10 Gy) 27/8 0.447 0.780
EBRT, external beam radiotherapy.Kong M, et al.  •  External Beam Radiotherapy in Hemophilic Arthropathy 
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growing epiphyses are particularly radiosensitive. Radiation-
induced bony growth disturbances apparently result from an 
arrest in chondrogenesis and vascular changes. The effects of 
radiation on bone growth are more serious for higher doses of 
radiation and for younger patients. Silverman et al. (20) report-
ed that the risk of epiphyseal slippage is about 47% in children 
irradiated while under the age of 4 yr, and about 5% in older chil-
dren. The frequency of occurrence rose dramatically for those 
patients who were less than 4 yr old at time of irradiation. How-
ever, in the relationship between dose and age at irradiation, no 
slippage occurred if less than 25 Gy were received by the epiph-
yseal plate. In conclusion, they found that patients below the 
age of 4 yr who received doses in excess of 25 Gy to the epiphy-
seal plate were at particular risk for slippage, and that it is the 
dose of radiation to the epiphysis that is the major cause of the 
complication. Hogeboom et al. (21) reported that with the ex-
ternal beam radiation therapy in 2,778 children with Wilms tu-
mor, they observed height deficits was zero for 16 children who 
received RT doses under 15 Gy at a mean age of 83 months. In 
our study, the authors delivered radiation doses for patients 
younger than 11 yr old of no more than 9 Gy. And, during the 
follow-up period, bony growth disturbances were not seen. 
  In summary, EBRT decreases intraarticular bleeding frequen-
cy in hemophilic arthritis patients with minimal complications. 
However, similar to radioisotope synovectomy, radiation-in-
duced chromosomal changes and secondary malignancies are 
a major concern with EBRT, and therefore, long-term studies 
are needed.
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